The aim of this report is to investigate the activity of ramucirumab in combination with paclitaxel in patients with metastatic gastric cancer (GC) and lung metastases. We retrospectively reviewed clinical data from patients with GC treated in second line with ramucirumab and paclitaxel according to the presence or not of lung metastases. Thirty-one patients were eligible. Five (16.1%) patients had lung metastases. The median progression-free survival was 156 days in patients without lung metastases compared with 54 days in patients with lung metastases. The median survival also showed a trend in favour of patients without lung metastases. Despite the small number of patients and the retrospective nature of the data, our analysis showed relatively poor efficacy of ramucirumab plus paclitaxel as a second-line treatment in patients with lung metastases from GC. Further studies are required to evaluate novel treatments in this subset of patients.
aDepartment of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, Division of Medical Oncology, Rionero
bUnit of Medical Oncology, Department of Oncology, Ospedale San Donato, Arezzo
cDepartment of Medicine, Surgery and Neurosciences, Medical Oncology Unit, University of Siena, Siena, Italy
dDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Moorabbin Campus, Bentleigh East, Victoria, Australia
Received 12 February 2019 Revised form accepted 19 March 2019
Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website, www.anti-cancerdrugs.com.
This work has been reported as an abstract in Abstract Book: Tumori J 2018; 104 (Suppl): 6–224.
Correspondence to Giandomenico Roviello, MD, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, Division of Medical Oncology, via Padre Pio 1, 85028 Rionero, Italy Tel: + 39 097 272 6255; fax: + 39 097 272 6716; e-mail: firstname.lastname@example.org